136 related articles for article (PubMed ID: 29394585)
1. [A Case of HER2-Positive Breast Cancer with Newly Diagnosed Stage IV That Responded to First-Line Pertuzumab and Trastuzumab-Based Therapy].
Yoshioka S; Hojo S; Toyoda Y; Maeura Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1214-1216. PubMed ID: 29394585
[TBL] [Abstract][Full Text] [Related]
2. [A Case of HER2-Positive Breast Cancer with Liver Metastases Showing Three Years of Complete Response to Combination Therapy with Trastuzumabplus Pertuzumab].
Fujimoto Y; Yamaguchi K; Ueno A; Sakurai R; Nagahisa Y; Imai S; Kawamoto K
Gan To Kagaku Ryoho; 2018 Mar; 45(3):459-461. PubMed ID: 29650905
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Hamaoka A; Matsuda T; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1097-100. PubMed ID: 27628551
[TBL] [Abstract][Full Text] [Related]
4. [Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response].
Ishiyama T; Yamaya H; Jinguu A; Matsumoto H
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1505-1507. PubMed ID: 33130751
[TBL] [Abstract][Full Text] [Related]
5. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
7. [A case of HER2-positive breast cancer for which preoperative chemotherapy with pertuzumab resulted in a pathological complete response].
Abe H; Yamazaki K; Yoneda K; Ogawa M; Kawasaki M; Yoneda G; Yoshimura M; Kameyama M
Gan To Kagaku Ryoho; 2015 Apr; 42(4):485-8. PubMed ID: 25963698
[TBL] [Abstract][Full Text] [Related]
8. [Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Tomida K; Kawai Y; Mori T; Kitamura M; Kato H; Sakai S; Shimizu T; Umeda T; Tatsumi M; Shimada K; Tani M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2435-2437. PubMed ID: 30692489
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
10. A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Inoue Y; Yamashita N; Tokunaga E; Tanaka K; Ueo H; Saeki H; Oki E; Yamamoto H; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1917-1921. PubMed ID: 28373460
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
12. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
13. [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
Nomura T; Sonoo H; Miyake A; Souda M; Yamamoto Y; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1607-10. PubMed ID: 18799922
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy].
Kanada Y; Matsuzaki H; Kobayashi H; Suzuki K; Sawada H; Senba Y; Yoshioka T; Note H; Sato Y; Miyazaki A; Natsume T; Tanaka H; Maruyama T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1509-11. PubMed ID: 26805079
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
17. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
18. Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism.
Schoellhammer HF; Hsu F; Vito C; Chu P; Park J; Waisman J; Kim J
BMC Cancer; 2014 Apr; 14():242. PubMed ID: 24708527
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
20. [A Case of HER2 Positive Locally Advanced Breast Cancer Successfully Treated with a Combination Therapy of Eribulin, Trastuzumab and Pertuzumab].
Sazuka T; Kimura M; Kamata T; Isozaki T; Urahama R; Tasaki K; Sugamoto Y; Watanabe Y; Asai Y; Fukunaga T; Matsubara H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2470-2472. PubMed ID: 30692501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
